Medical News

RSS

Tyco declares quarterly dividend of CHF 0.22 per share

The Board of Directors of Tyco International Ltd. today declared a quarterly dividend of 0.22 Swiss Francs (CHF) per share, payable on August 25, 2010 to shareholders of record at the close of business on July 30, 2010, subject to a required filing with the Swiss Commercial Register.

8 Jul 2010

KHN column -- High-risk pools: A rare opportunity for bipartisanship

In his latest Kaiser Health News column, Harold Pollack writes: "This month a key program created by the new health overhaul law, the Pre-Existing Condition Insurance Plan, becomes operational in many states. Over the next 40 months, this high-risk insurance pool will provide $5 billion to cover Americans who face the dual challenges of chronic illness and uninsurance.

8 Jul 2010

Onda celebrates 2000th hydrophone shipment

Onda Corporation, the global leader in ultrasound measurements, celebrated the 2000th hydrophone shipment. The hallmark unit, a polymer-based HNP hydrophone, shipped to St. Jude's Medical where it is used to test the acoustic properties of their medical transducers in production.

8 Jul 2010

CompuMed secures extended contracts with Oklahoma and Arizona's departments of corrections

CompuMed, Inc., a medical informatics and telemedicine services company, has secured extended contracts to provide its signature CardioGram™ electrocardiogram (ECG) remote interpretation systems and over-read services for the Oklahoma Department of Corrections (OKDOC) and Arizona Department of Corrections (ADC) at selected facilities throughout both states. The OKDOC rents 21 CardioGram systems, and the ADC owns 45 CardioGram systems.

8 Jul 2010

Infinity obtains global rights to Intellikine's portfolio of inhibitors of delta and gamma isoforms of PI3K

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, and Intellikine, Inc., a leader in the development of small molecule drugs targeting the PI3K/mTOR pathway, today announced an agreement under which Infinity obtained global development and commercialization rights to Intellikine's portfolio of inhibitors of the delta and gamma isoforms of phosphoinositide-3-kinase.

8 Jul 2010

pSivida submits MAA for Iluvien to UK MHRA

pSivida Corp., a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that its licensee, Alimera Sciences has submitted a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom (UK) for Iluvien®.

8 Jul 2010

MDS Nordion to supply Mo-99 on weekly basis to Lantheus Medical Imaging

MDS Nordion, a leading provider of products and services to the global health science market, today announced it has signed a new contract with its primary customer, Lantheus Medical Imaging, Inc. for the supply of Molybdenum-99.

8 Jul 2010

Study demonstrates causal relationship between onset of Creutzfeldt-Jakob disease and general surgery

A new study spearheaded by Spanish scientists demonstrates a causal relationship between the onset of Creutzfeldt-Jakob disease (CJD), caused by a protein called a prion, and general surgery. CJD manifests itself in hereditary acquired; and sporadic forms, or for unknown reasons, which accounts for the majority of cases.

8 Jul 2010

Cannabis Science enters into long-term lease on 9,500 square foot facility in Denver, Colorado

Cannabis Science, Inc., a pioneering U.S. biotech company developing pharmaceutical cannabis products, is pleased to announce that it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.

8 Jul 2010

PhotoMedex receives multi-million dollar order from AMICO Group to purchase XTRAC laser systems

PhotoMedex, Inc. announced that the Company has received from AMICO Group, its distributor in the Middle East, a multi-million dollar order to purchase XTRAC laser systems that will be installed in hospitals throughout the Kingdom of Saudi Arabia. The order includes customary terms and conditions, including advanced payments and letters of credit covering the purchase order. Delivery is expected to be in the third and fourth quarters of this year.

8 Jul 2010

Calithera Biosciences completes Series A financing totaling $40M

Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S. Venture Partners, Advanced Technology Ventures, Delphi Ventures and Mission Bay Capital also participating in the round. The capital will be used to support the company's pioneering efforts to develop activators of caspases, the proteases that promote apoptotic cell death, for the treatment of cancer and other proliferative diseases.

8 Jul 2010

Rockwell Medical completes End of Phase II meeting with FDA regarding SFP

Rockwell Medical, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease, chronic kidney disease, and iron deficiency anemia, announced today that it has successfully completed an End of Phase II meeting with the U.S. Food and Drug Administration regarding the Company's lead drug candidate Soluble Ferric Pyrophosphate, a novel continuous iron-replacement therapy designed to treat iron deficiency anemia in hemodialysis patients.

8 Jul 2010

Fibrocell Science completes enrollment in azficel-T histology study

Fibrocell Science, Inc., a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today the completion of enrollment of and first treatment visits for participants in its histology study (IT-H-001) of azficel-T. An autologous cell therapy, azficel-T is currently under review by the U.S. Food and Drug Administration for the treatment of moderate to severe nasolabial fold wrinkles.

8 Jul 2010

WSBI, University of Colorado sign licensing agreement for TCISM targets

Western States Biopharmaceuticals, Inc., a privately-held biotechnology company focusing on the development of novel therapies to treat inflammatory disease, and the University of Colorado announced today that they have entered into a licensing agreement for approaches to inhibiting newly discovered T cell Cytokine Inducing Surface Molecules, or TCISM autoimmune disease drug discovery targets.

8 Jul 2010

Elsevier and Legacy Interactive release Top Doc iPhone app for medical students, practitioners

Elsevier, a world leader in health care, medical publishing and online solutions, and video game developer and publisher Legacy Interactive(R), announced today the release of Top Doc, an iPhone app that features medical content and quizzes designed to let medical students, residents and junior faculty practice and improve their visual diagnosis skills. Elsevier and Legacy Interactive(R) developed the app's interactive format to engage and challenge users with multiple elements.

8 Jul 2010

Allscripts Electronic Health Record chosen for PAL

Allscripts announced today that Central Penn Management Group, a management services organization in Central Pennsylvania, has selected the Allscripts Electronic Health Record for Physicians Alliance Ltd., a 120-provider, independent multispecialty group that CPMG manages.

8 Jul 2010

Advanced Life Sciences announces positive results from preclinical studies of Restanza IV

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from preclinical toxicology and pharmacokinetic studies of an intravenous (IV) formulation of its novel antibiotic, Restanza™ that support its use in a hospital setting.

8 Jul 2010

First patient enrolled in Boston Scientific's MultiSENSE clinical trial

Boston Scientific Corporation today announced enrollment of the first patient in its MultiSENSE clinical trial. The trial is designed to evaluate multiple physiologic sensors in the Company's COGNIS cardiac resynchronization therapy defibrillators. Boston Scientific plans to use the trial data to help develop a clinical alert that identifies the early onset of worsening heart failure.

8 Jul 2010

Alimera Sciences submits MAA for Iluvien to MHRA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals has submitted a Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency in the United Kingdom for Iluvien (fluocinolone acetonide intravitreal insert).

8 Jul 2010

Shire files patent infringement lawsuit against Zydus

Shire plc, the global specialty biopharmaceutical company, announces that its subsidiaries Shire Development Inc. and Shire Pharmaceutical Development Inc. have filed a lawsuit in the U.S. District Court for the District of Delaware against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals, Inc. for the infringement of U.S. Patent No. 6,773,720.

8 Jul 2010